(Q35034324)

5 August 2017

1 reference

title

Fondaparinux: a new antithrombotic agent (English)

1 reference

5 August 2017

1

Judy W M Cheng

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

published in

Clinical Therapeutics

1 reference

5 August 2017

volume

24

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1757-69; discussion 1719

1 reference

5 August 2017

cites work

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Thrombosis and the pharmacology of antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Molecular and cellular biology of blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Prevention of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980077-7

7 January 2021

10.1016/S0149-2918(02)80077-7

Identifiers

DOI

1 reference

5 August 2017

1 reference